The prevalence of type 2 diabetes mellitus is increasing worldwide. The number of people living with diabetes is expected to more than double from 171 million in 2000 to 366 million by 2030 (1). In the United States, an estimated 9.3% of adults aged 20 years or older have diabetes (6.5% diagnosed and 2.8% undiagnosed), a significant increase (p = 0.0002) from the 5.1% prevalence of diagnosed diabetes in the previous decade. Increases have been seen in all age groups, both sexes and all race/ethnic groups (2).

Risk factors for the development of diabetes include overweight or obesity, physical inactivity, hypertension, dyslipidaemia, family history, impaired glucose tolerance and impaired fasting glucose. Type 2 diabetes is an important risk factor for cardiovascular disease (3) and is regarded as a coronary heart disease ‘risk equivalent’ by the Adult Treatment Panel III of the National Cholesterol Education Program (4). Individuals with type 2 diabetes have a two- to threefold higher risk of cardiovascular disease than their non-diabetic counterparts (5), and, in the United States, the majority (65%) of deaths in people with diabetes are due to heart disease and stroke (6). Diabetes is also associated with a significant increase in risk of comorbid hypertension and dyslipidaemia (7).

The higher incidence of cardiovascular disease in patients with type 2 diabetes can be explained in part

SUMMARY

Type 2 diabetes mellitus is a worldwide epidemic with considerable health and economic consequences. Diabetes is an important risk factor for cardiovascular disease, which is the leading cause of death in diabetic patients, and decreasing the incidence of diabetes may potentially reduce the burden of cardiovascular disease. This article discusses the clinical trial evidence for modalities associated with a reduction in the risk of new-onset diabetes, with a focus on the role of antihypertensive agents that block the renin–angiotensin system. Lifestyle interventions and the use of antidiabetic, anti-obesity, and lipid-lowering drugs are also reviewed. An unresolved question is whether decreasing the incidence of new-onset diabetes with non-pharmacologic or pharmacologic intervention will also lower the risk of cardiovascular disease. A large ongoing study is investigating whether the treatment with an oral antidiabetic drug or an angiotensin-receptor blocker will reduce the incidence of new-onset diabetes and cardiovascular disease in patients at high risk for developing diabetes.
by the increased prevalence of comorbid risk factors (8,9). However, even after correction for these factors, diabetes confers a 1.5- to 4.5-fold increase in risk of myocardial infarction in women, a 1.5- to twofold increase in risk of myocardial infarction in men, and a 1.5- to twofold increase in risk of death in both sexes (10).

Chronic hyperglycaemia is the defining characteristic of diabetes and the target of antidiabetic therapy but the benefits of reducing elevated glucose values and the specific target that should be achieved remain uncertain. While maintenance of glycaemic control has been shown to reduce the risk of microvascular complications, including retinopathy, nephropathy and neuropathy (11,12), studies of the effect of glycaemic control on the risk of macrovascular complications have produced conflicting results. A meta-analysis of prospective cohort studies that assessed the association between glycosylated haemoglobin (A1C) levels and macrovascular disease in patients with diabetes observed that, in patients with type 2 diabetes, each one-percentage point increase in A1C is associated with an 18% increase in risk of cardiovascular disease (13). In the United Kingdom Prospective Diabetes Study, intensive glycaemic control to an average A1C of 7% in patients with type 2 diabetes over a 10-year follow-up period reduced the risk of microvascular, but not macrovascular, complications compared with an average A1C of 7.9% (12). In the 6.5-year Diabetes Control and Complications Trial (DCCT), intensive treatment compared with conventional treatment in patients with type 1 diabetes was associated with 76% and 54% reductions in the risk of development and progression of retinopathy, respectively (p < 0.001 for both), but no reduction was noted in macrovascular disease (11). It was, however, in the Epidemiology of Diabetes Interventions and Complications Study, an 11-year followup to DCCT, where intensive treatment reduced the risk of any cardiovascular disease event by 42% (p = 0.02) and the risk of non-fatal myocardial infarction, stroke, or death from cardiovascular disease by 57% (p = 0.02) (14).

Two recently published landmark trials – the Action in Diabetes and Vascular Disease: Pretaraz and Diamicon Modified Release Controlled Evaluation (ADVANCE) (15) and the Action to Control Cardiovascular Risk in Diabetes (ACCORD) (16) – failed to demonstrate that intensive glycaemic control reduces cardiovascular disease risk in those with long-standing type 2 diabetes. In both the 5-year ADVANCE trial and the planned 4- to 8-year ACCORD trial, intensive glucose control (defined as a target A1C level < 6.5% in ADVANCE and < 6.0% in ACCORD) had no significant effects on the incidence of cardiovascular disease events compared with standard glucose control. Moreover, in ACCORD, a significant increase in all-cause mortality in the intensive treatment group led to premature discontinuation of that arm of the trial at 3.5 years. Taken together, the results of ADVANCE and ACCORD suggest that 7% remains an appropriate A1C target in those with long-standing type 2 diabetes (17,18). While the results of the previous trials (including ADVANCE) confirm the role of more aggressive glycaemic control in reducing the risk of microvascular complications, the lack of effect on cardiovascular disease events may have important implications for our understanding of the pathogenesis and reversibility of macrovascular complications of diabetes. Taken together, these results suggest the need for earlier intervention in those with type 2 diabetes as well as the need to address non-glycaemic comorbid risk factors, such as hypertension and dyslipidaemia (18).

### New-onset diabetes and cardiovascular disease

The current criteria for diagnosis of diabetes are a fasting plasma glucose level ≥ 126 mg/dl, symptoms of hyperglycaemia, and a casual plasma glucose level ≥ 200 mg/dl, or a 2-h postchallenge plasma glucose level ≥ 200 mg/dl during an oral glucose tolerance test; fasting plasma glucose < 100 mg/dl and 2-h plasma glucose < 140 mg/dl are considered ‘normal’ (19). The intermediate hyperglycaemic state that does not meet the threshold for diagnosis of overt diabetes is termed ‘prediabetes’ and comprises impaired fasting glucose (fasting plasma glucose 100–125 mg/dl) and impaired glucose tolerance (2-h plasma glucose 140–199 mg/dl) (19). Prediabetes, which affects 57 million adults and children in the United States (20), imparts an increased risk of both progression to overt diabetes and cardiovascular disease (21) making it a potential target for treatment.

A comparison of recommendations for treatment of prediabetes by the American Diabetes Association, American Heart Association and American College of Endocrinology is attached (Table 1). For the prevention or delay of type 2 diabetes in patients with impaired fasting glucose or impaired glucose tolerance, the American Diabetes Association suggests ‘lifestyle counselling’ [weight loss of 5–10% and at least 150 min/week of moderate activity (e.g. walking)]. In individuals at very high risk of developing diabetes (the presence of impaired fasting glucose and impaired glucose tolerance plus other risk factors), the addition of the oral antidiabetic drug metformin is recommended (19). The American Heart
Table 1 Recommendations for treatment of patients with pre-diabetes by the American Diabetes Association, American Heart Association and American College of Endocrinology

| Lifestyle | American Diabetes Association (21) | American Heart Association (4)* | American College of Endocrinology (22) |
|----------|-----------------------------------|---------------------------------|----------------------------------------|
|          | Weight loss of 5–10% body weight and ~30 min/day moderate-intensity physical activity | Weight loss of 7–10% body weight within 6–12 months ≥ 30 min/day moderate-intensity exercise | 30–60 min moderate-intensity physical activity/day at least 5 times/week Low-fat diet with adequate fibre |
| Glucose  | Metformin in patients with IFG and IGT and any risk factors for diabetes† | | |
| Blood pressure | BP < 140/90 mmHg | BP medication(s) as needed to achieve goal BP ACEI or ARB as first-line agent |
| Lipids   | Depending on risk, LDL-C < 130, < 100 or < 70 mg/dl; non-HDL-C < 160, < 130 or < 100 mg/dl | Lipid-lowering drug therapy with possible addition of fibrate or nicotinic acid | LDL-C: < 100 mg/dl Non-HDL-C: < 130 mg/dl ApoB: < 90 mg/dl |
| Prothrombotic state | Depending on risk, consider low-dose aspirin therapy or clopidogrel when aspirin is contraindicated | | Aspirin in therapy unless patient is at increased risk of GI, intracranial or other haemorrhagic condition |

ACEI, angiotensin converting-enzyme inhibitor; ApoB, apolipoprotein B; ARB, angiotensin receptor blocker; BP, blood pressure; GI, gastrointestinal; HDL-C, high-density lipoprotein cholesterol; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; LDL-C, low-density lipoprotein cholesterol; MetS, metabolic syndrome; NA, non-alcoholic; PCOS, polycystic ovary syndrome. *American Heart Association guidelines pertain to patients with the metabolic syndrome, defined as any three of the following features: elevated waist circumference (≥ 102 cm (≥ 40 inches) in men or ≥ 88 cm (≥ 35 inches) in women), elevated triglycerides (≥ 150 mg/dl (1.7 mmol/l)) or drug treatment for elevated triglycerides, reduced HDL-C (< 40 mg/dl (< 1.03 mmol/l) in men or < 50 mg/dl (< 1.3 mmol/l)) in women or drug treatment for reduced HDL-C, elevated blood pressure (≥ 130/85 mmHg or antihypertensive drug treatment), elevated fasting glucose (≥ 100 mg/dl) or drug treatment for elevated glucose. †Risk factors for diabetes = age < 60 years, body mass index ≥ 35 kg/m², family history of diabetes in first-degree relatives, elevated triglycerides, reduced HDL-C, hypertension, glycosylated haemoglobin > 6.0%.

Association recommendations for reducing the risk of new-onset diabetes in patients with the metabolic syndrome and impaired fasting glucose or impaired glucose tolerance include weight reduction, increased physical activity, metformin, thiazolidinediones and acarbose, an intestinal α-glucosidase inhibitor. In a recently released consensus statement on the treatment of patients with prediabetes, the American College of Endocrinology recommends targeting hyperglycaemia and comorbid risk factors, including hypertension and dyslipidaemia, with lifestyle modifications and add-on pharmacologic therapy, where needed (22). Specifically, the guidelines, while short of clinical trial evidence, recommend that patients with prediabetes and hypertension be treated with antihypertensive agents that include those that inhibit the renin–angiotensin system (RAS) – angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) – to the same blood pressure goal recommended for patients with overt diabetes, i.e. < 130/80 mmHg. Likewise, the consensus document recommends that lipid goals in patients with prediabetes should be the same as those with diabetes: low-density lipoprotein cholesterol < 100 mg/dl, non-high-density lipoprotein cholesterol < 130 mg/dl, and apolipoprotein B < 90 mg/dl.

Lifestyle intervention
Lifestyle modification aimed at weight loss has been shown to be highly effective in preventing or delaying the development of diabetes in high-risk subjects (Table 2). In the Finnish Diabetes Prevention Study, 522 obese adults with impaired glucose tolerance were randomised to a lifestyle intervention group of individualised counselling aimed at reducing weight.
and increasing physical activity or to placebo (23). After a mean follow-up of 3.2 years, the incidence of diabetes was 11% in the intervention group compared with 23% in the control group, a significant 58% risk reduction (p < 0.001). Similar results were seen in the Diabetes Prevention Program (DPP), conducted in the USA, in which 3234 non-diabetic obese patients with elevated fasting and postload plasma glucose concentrations were randomised to one of the three interventions: a lifestyle programme with goals of ≥7% weight loss and ≥150 min of physical activity/week; pharmacologic therapy with metformin or placebo (24). After a mean 2.8 years, lifestyle intervention reduced the incidence of new-onset diabetes by 58% and metformin-based therapy reduced the risk of diabetes by 31%, compared with placebo (p < 0.001 for both comparisons).

Although neither the Finnish Diabetes Prevention Study nor the DPP was designed to assess cardiovascular disease benefit, cardiovascular disease risk factors were reduced in both trials. In the Finnish study, at the end of 1 year, patients in the intervention group had significantly greater reductions in weight (p < 0.001), systolic (p = 0.007) and diastolic (p = 0.02) blood pressure, serum triglycerides (p = 0.001), and fasting plasma glucose levels (p < 0.001) (23). In the DPP, the incidence of metabolic syndrome was reduced by 41% in the lifestyle group (p < 0.001) and by 17% in the metformin group (p < 0.03) compared with placebo (25).

### Table 2 Effects of lifestyle modification and pharmacologic therapy with antidiabetic, anti-obesity and lipid-lowering drugs on the risk of new-onset diabetes in selected key randomised trials

| Study                                      | Comparators                                      | Duration (years)* | Patient population                                                                 | Relative risk (95% CI) | p-Value | Prespecified end-point? |
|--------------------------------------------|--------------------------------------------------|-------------------|------------------------------------------------------------------------------------|------------------------|---------|------------------------|
| **Lifestyle intervention**                 | Finnish Diabetes Prevention Study (23)           | 3.2               | 522 obese patients with IGT                                                       | 0.4 (0.3–0.7)          | < 0.001 | Yes                    |
|                                            | DPP (24)                                         | 2.8               | 3234 non-diabetic obese patients with IFG and IGT                                  | 0.42 (0.34–0.52)       | < 0.001 | Yes                    |
|                                            |                                                  |                   |                                                                                    | 0.69 (0.57–0.83)       | < 0.001 |                        |
| **Antidiabetic drugs**                     | TRIPOD (26)                                      | 2.5 (median)      | 266 Hispanic women with previous gestational diabetes                             | 0.45 (0.25–0.83)       | < 0.01  | Yes                    |
|                                            | STOP-NIDDM (27)                                  | 3.3               | 1368 patients with IGT                                                            | 0.75 (0.63–0.90)       | 0.0015  | Yes                    |
|                                            | DREAM (29)                                       | 3.0 (median)      | 5269 patients with IFG and/or IGT but without CVD or renal disease                 | 0.38 (0.33–0.44)       | < 0.0001| Yes                    |
| **Anti-obesity drug**                      | XENDOS (31)                                      | 4.0               | 3305 non-diabetic obese (BMI ≥ 30 kg/m²) patients with normal or IGT               | 0.63 (0.46–0.86)       | 0.0032  | Yes                    |
| **Lipid-lowering drugs**                   | WOSCOPS (32)                                     | 4.9               | 5974 non-diabetic men aged 45–64 years with dyslipidaemia and no history of MI     | 0.70 (0.50–0.99)       | 0.042   | No                     |
|                                            | Heart Protection Study (33)                      | 5.0               | 14,573 patients with occlusive arterial disease                                   | 1.15 (0.99–1.34)       | ns      | Yes                    |
|                                            | LIPID (34)                                       | 6.0               | 6,997 patients with dyslipidaemia                                                   | 0.89 (0.70–1.13)       | ns      | No                     |
|                                            | ASCOT-LLA (35)                                   | 3.3 (median)      | 19,342 hypertensive patients with ≥ 3 other CVD risk factors                      | 1.15 (0.91–1.44)       | ns      | Yes                    |

*Mean years of follow-up unless indicated. ASCOT-LLA, Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm; BMI, body mass index; CAD, coronary artery disease; CI, confidence interval; CVD, cardiovascular disease; DPP, Diabetes Prevention Program; DREAM, Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication; HF, heart failure; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; LIPID, Long-Term Intervention with Pravastatin in Ischemic Disease; LVH, left ventricular hypertrophy; MI, myocardial infarction; ns, not significant; STOP-NIDDM, Study to Prevent Non-Insulin-Dependent Diabetes Mellitus; TRIPOD, Troglitazone in Prevention of Diabetes; WOSCOPS, West of Scotland Coronary Prevention Study; XENDOS, Xenical in the Prevention of Diabetes in Obese Subjects.
Pharmacotherapy for the prevention of diabetes

A number of studies have assessed the impact of different classes of antidiabetic drugs on prevention of diabetes (Table 2) (26–28). New-onset diabetes was reduced in the Study to Prevent Non-insulin-dependent diabetes mellitus (STOP-NIDDM), in which 1368 patients with impaired glucose tolerance were treated with acarbose or placebo (27). At 39-month followup, new-onset diabetes occurred in 32% of patients in the acarbose group vs. 42% in the placebo group (risk ratio, 0.75; p = 0.0015). Treatment with acarbose was also associated with an increase in reversion to normoglycaemia. In a secondary analysis of STOP-NIDDM, acarbose also reduced the incidence of cardiovascular disease events from 4.7% to 2.1% (hazard ratio, 0.51; p = 0.03), mainly as a result of a reduction in myocardial infarction (hazard ratio, 0.09; p = 0.02) (28). Moreover, acarbose was associated with a reduced incidence of new-onset hypertension (hazard ratio, 0.66; p = 0.006), an important cardiovascular disease risk factor.

Similar results were achieved in the glycaemic arm of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial, in which 5269 patients with impaired fasting glucose and/or impaired glucose tolerance and no previous cardiovascular disease or significant renal disease were randomised to treatment with rosiglitazone or placebo (and ramipril or placebo) in a 2 × 2 factorial design (29). During a median 3-year followup, 11.6% of patients in the rosiglitazone group and 26.0% in the placebo group developed the primary composite outcome of new-onset diabetes or death (hazard ratio, 0.40; p < 0.0001). When the components of the primary outcome were analysed separately, rosiglitazone was associated with a significant reduction in the incidence of new-onset diabetes (10.6% vs. 25.5%; hazard ratio, 0.38), but rates of all-cause mortality were similar in both treatment groups. Reversion to normoglycaemia was significantly more common in the rosiglitazone group (50.5% vs. 30.3%; hazard ratio, 1.71); however, there was no significant difference in cardiovascular disease event rates between the treatment groups.

The Outcome Reduction with an Initial Glargine Intervention (ORIGIN) may help to clarify the effect of glycaemic control on cardiovascular disease risk. In ORIGIN, 12,612 people aged 50 years or older with evidence of cardiovascular disease and impaired fasting glucose, impaired glucose tolerance or diabetes were randomised to treatment with insulin glargine or standard glycaemic care (and long-chain ω-3 polyunsaturated fatty acids or placebo) to determine the effect of these treatments on cardiovascular disease risk (30). The anticipated end date of the study is October 2009.

The anti-obesity drug orlistat, an inhibitor of pancreatic and gastrointestinal lipases, has been shown to reduce the risk of new-onset diabetes (Table 2). In the 4-year Xenical in the Prevention of Diabetes in Obese Subjects trial, which included 3305 non-diabetic obese (body mass index ≥ 30 kg/m²) individuals with normal or impaired glucose tolerance, orlistat plus lifestyle interventions reduced the incidence of new-onset diabetes by 37.3% (p = 0.0032) compared with placebo plus lifestyle intervention (31). The orlistat group also experienced significantly greater reductions in systolic and diastolic blood pressures, low-density lipoprotein cholesterol, and fasting blood glucose levels and a significantly greater increase in high-density lipoprotein cholesterol levels.

Although lipid-lowering agents such as statins have been shown to reduce the risk of cardiovascular disease in patients with diabetes, post hoc analyses of placebo-controlled trials have reported conflicting results regarding the effects of statins on new-onset diabetes (Table 2). In the 4.9-year West of Scotland Coronary Prevention Study, which included 5974 non-diabetic men aged 45–64 years with dyslipidaemia and no prior history of myocardial infarction, pravastatin reduced the incidence of new-onset diabetes by 30% (p = 0.042) compared with placebo (32). By contrast, in the Heart Protection Study (33), the Long-Term Intervention with Pravastatin in Ischemic Disease (34), and the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (35), statin therapy had no impact on the development of diabetes.

Role of antihypertensive agents

Patients at high risk for developing diabetes are likely to also be hypertensive. Indeed, individuals with elevated blood pressure are 2.5–5 times more likely than their normotensive counterparts to develop type 2 diabetes (36,37). Until relatively recently, discussions regarding the use of antihypertensive agents and diabetes focused on the negative metabolic effects of β-blockers and diuretics (38). More recently, however, attention has been focused on the potential metabolic benefits of RAS inhibition with ACE inhibitors and ARBs.

The effects of the β-blocker atenolol with or without a thiazide diuretic (bendroflumethiazide) were evident in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) (39). In the 5.5-year trial, which included 15,257 patients with hypertension and at least three other
cardiovascular disease risk factors, treatment with the calcium channel blocker (CCB) amlodipine (with or without the ACE inhibitor perindopril) was associated with a 16% reduction in risk of cardiovascular disease events and a 30% reduction in risk of new-onset diabetes compared with treatment with atenolol ± bendroflumethiazide (39). However, a new subgroup analysis of ASCOT-BPLA concluded that, along with baseline fasting plasma glucose and body mass index, the use of atenolol ± diuretic was among the major determinants of risk of new-onset diabetes (40). The authors propose that the reduction in diabetes associated with the amlodipine-based regimen may be caused by the metabolically protective effect of perindopril combined with the neutral effects of amlodipine, in contrast to the negative metabolic effects of both atenolol and bendroflumethiazide.

Analyses of several clinical trials using antihypertensive agents in patients with and without hypertension have demonstrated that RAS blockade significantly reduces the risk of new-onset diabetes in patients treated with ACE inhibitors (41–44) or ARBs (45–48), compared with diuretics, β-blockers, CCBs, or placebo (Table 3). These findings are confirmed by the results of two recent meta-analyses (49,50). In the first meta-analysis of 13 trials that included 93,451 patients without diabetes at baseline, randomisation to ACE inhibitor- or ARB-based therapy was associated with a 26% reduction in risk of developing diabetes (p < 0.001) (49). In the second,

| Study | Comparators | Duration (years)* | Patient population | Relative risk (95% CI) | p-Value | Prespecified end-point? |
|-------|-------------|------------------|--------------------|------------------------|---------|------------------------|
| ACE inhibitors | | | | | | |
| CAPPP (41) | Captopril vs. β-blocker/diuretic | 6.1 | 10,985 hypertensive patients | 0.79 (0.67–0.94) | 0.007 | Yes |
| HOPE (42) | Ramipril vs. placebo | 5 | 9297 patients with history of CAD, stroke, PVD, for diabetes and ≥ 1 other CVD risk factor | 0.66 (0.51–0.85) | < 0.001 | Yes |
| ALLHAT (43) | Lisinopril vs. diuretic | 4.9 | 33,357 hypertensive patients with ≥ 1 other CVD risk factor | 0.70 (0.56–0.86) | < 0.001 | No |
| PEACE (44) | Trandolapril vs. placebo | 4.8 (median) | 8290 with stable CAD | 0.83 (0.72–0.96) | 0.001 | No |
| ASCOT-BPLA (39) | Amlodipine (±perindopril) vs. atenolol (±diuretic) | 5.5 (median) | 19,257 hypertensive patients with ≥ 3 other CVD risk factors | 0.70 (0.63–0.78) | < 0.0001 | Yes |
| DREAM (51) | Ramipril vs. placebo | 3.0 (median) | 5269 patients with IFG and/or IGT but without CVD or renal disease | 0.91 (0.80–1.03) | ns | Yes |
| ARBs | | | | | | |
| LIFE (45) | Losartan vs. atenolol/placebo/other drugs | 4.8 | 9193 hypertensive patients with LVH | 0.75 (0.63–0.86) | 0.001 | Yes |
| SCOPE (46) | Candesartan vs. placebo/other drugs | 3.7 | 4964 hypertensive patients aged 70–89 years | 0.81 (0.61–1.02) | 0.09 | No |
| CHARM (47) | Candesartan vs. placebo | 3.1 | 7599 patients with HF | 0.78 (0.64–0.96) | 0.02 | Yes |
| VALUE (48) | Valsartan vs. amlodipine | 4.2 | 15,245 hypertensive patients with high risk of CVD events | 0.77 (0.69–0.86) | < 0.0001 | Yes |
| TRANSCEND (57) | Telmisartan vs. placebo | 4.7 (median) | 5926 patients intolerant to ACE inhibitors with CAD, PVD, CBVD or diabetes with end-organ damage | 0.85 (0.71–1.02) | 0.081 | Yes |
| ACE inhibitor./ARB combination | | | | | | |
| ONTARGET (56) | Telmisartan vs. ramipril; telmisartan + ramipril vs. ramipril | 4.7 (median) | 25,620 patients with CAD, PVD, CBVD or diabetes with end-organ damage | 1.12 (0.97–1.29) | ns | Yes |
| | | | | | | |

*Mean years of follow-up unless indicated. ACE, angiotensin-converting enzyme; ALLHAT, Antihypertensive and Lipid-Lowering treatment to Prevent Heart Attack Trial; ARB, angiotensin receptor blocker; ASCOT-BPLA, Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm; CAD, coronary artery disease; CAPPP, Captopril Prevention Project; CBVD, cerebrovascular disease; CHARM, Candesartan in Heart failure – Assessment of Reduction in Morbidity and Mortality; CI, confidence interval; CVD, cardiovascular disease; DREAM, Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication; HF, heart failure; HOPE, Heart Outcomes Protection Study; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; LIFE, Losartan Intervention For End-point reduction in hypertension; LVH, left ventricular hypertrophy; ns, not significant; ONTARGET, Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial; PEACE, Prevention of Events with Angiotensin-Converting Enzyme Inhibition; PVD, peripheral vascular disease; SCOPE, Study on Cognition and Prognosis in the Elderly; TRANSCEND, Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease; VALUE, Valsartan Long-term Use Evaluation.
a separate network meta-analysis of 22 trials with 143,153 participants without diabetes at study outset, ARBs and ACE inhibitors were associated with the lowest proportion of subjects developing diabetes during clinical trial follow-up compared with other classes of antihypertensive agents (odds ratio, 0.57 for ARBs, p < 0.0001; and 0.67 for ACE inhibitors, p < 0.0001, using initial diuretic therapy as a standard of comparison) (50). These results are limited, however, by the fact that new-onset diabetes was not a prespecified primary or secondary outcome measure in a number of the trials included in the analysis.

Several recently completed trials using ACE inhibitors or ARBs included new-onset diabetes as a prespecified outcome measure. In the hypertension arm of the 3-year DREAM trial, the incidence of the primary composite end-point of new-onset diabetes or death was similar in the ramipril and the placebo groups (18.1% vs. 19.5%; hazard ratio, 0.91; p = 0.15) (51). There was no significant difference in the incidence of new-onset diabetes or cardiovascular disease in patients treated with ramipril compared with placebo. Moreover, a new analysis of DREAM found no difference in the rates of a prespecified secondary cardiorenal end-point in either treatment group (52). The failure of ramipril to reduce the incidence of new-onset diabetes and cardiovascular disease in this trial may be explained by several features of the study design, including the trial’s short duration (median 3 years vs. median ~4.5 years in previous RAS blocker trials) and the relatively low-risk profile of trial participants (mean age 55 years, mean blood pressure 136/83 mmHg; no history of significant cardiovascular disease or renal disease), suggesting that the degree of baseline RAS activation in the study participants was lower than that in the previous trials. Moreover, DREAM was placebo controlled, which reduced the possibility that the use of diabetogenic β-blockers or diuretics as comparator drugs confounded the results (53).

New-onset diabetes was a prespecified secondary end-point in the Valsartan Long-Term Use Evaluation (VALUE), which randomised 15,245 patients aged 50 years or older with hypertension and high risk of cardiovascular disease events to a mean of 4.2 years of valsartan- or amlodipine-based therapy (48). Although there were no statistically significant differences in the incidence of the primary composite cardiac end-point or in all-cause mortality, the incidence of new-onset diabetes was 23% lower in the valsartan group compared with the amlodipine group (13% vs. 41%; hazard ratio, 0.77). A post hoc analysis of the VALUE trial indicated that the risk of cardiac morbidity (defined as myocardial infarction or heart failure) in patients who developed diabetes during the 4.2-year followup was intermediate between that of those who had diabetes at baseline and those who did not develop diabetes at any point (54). Diabetes at baseline was associated with a twofold increase in risk of cardiac morbidity (hazard ratio, 2.20; p < 0.0001), while new-onset diabetes was associated with a 43% increase in risk of cardiac morbidity (p = 0.0008), primarily due to increased risk of congestive heart failure. Nonetheless, there was no difference in risk of the primary composite end-point of cardiac morbidity and mortality between those who developed new-onset diabetes and those who did not (hazard ratio, 1.10; p = 0.3447). Interestingly, new-onset diabetes was also associated with a decreased risk of all-cause mortality (hazard ratio, 0.61; p = 0.0001), possibly due to the increased use of aspirin, β-blockers, diuretics and statins in patients who developed diabetes compared with those who remained normoglycaemic (54,55).

New-onset diabetes was a secondary end-point in both the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) (56) and the Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (TRANSCEND) (57). The similarly designed 56-month trials both included high-risk patients with coronary, peripheral, or cerebrovascular disease or diabetes with end-organ damage and shared the primary composite outcome of cardiovascular disease death, myocardial infarction, stroke or hospitalisation for heart failure. In ONTARGET, which randomised 25,620 patients to ramipril, telmisartan or a combination of the two drugs, the primary outcome occurred at similar rates in the three treatment groups. Likewise, although new-onset diabetes was least common in the combination therapy group (6.1% for the combination vs. 6.7% in the ramipril group and 7.5% in the telmisartan group), the differences were not significant (56). TRANSCEND compared telmisartan to placebo in 5926 patients intolerant to ACE inhibitors. Telmisartan had placebo-like tolerability. Despite a 4-mmHg weighted difference in systolic blood pressure in favour of telmisartan over placebo, the primary outcome occurred at similar rates in both treatment groups. Although new-onset diabetes occurred less frequently in the telmisartan group, the difference was not significant (57). Whether this occurred because of the excellent use of background therapy that minimised any incremental benefit that telmisartan might provide remains unclear.

Recent analyses of metabolic and clinical outcomes in non-diabetic patients in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack
Trial (ALLHAT) confirm the metabolic benefits of RAS inhibitors compared with diuretics but fail to demonstrate a commensurate reduction in cardiovascular disease events. ALLHAT, which did not include new-onset diabetes as a prespecified outcome, randomised patients aged 55 years or older with stage 1 or stage 2 hypertension and at least one additional cardiovascular disease risk factor to chlorthalidone, amlodipine or lisinopril for a mean of 4.9 years (43). Among patients without diabetes at baseline, the incidence of diabetes at 4 years was the greatest with chlorthalidone (11.6%), lower with amlodipine (9.8%; p = 0.04 vs. chlorthalidone), and the lowest in those treated with lisinopril (8.1%; p < 0.001 vs. chlorthalidone) (43). However, in patients with the metabolic syndrome at baseline, the incidence of new-onset diabetes was almost twice as high as in those without the metabolic abnormality at baseline: 17.1% in the chlorthalidone group, 16.0% in the amlodipine group and 12.6% in the lisinopril group (p < 0.05 for lisinopril vs. chlorthalidone), compared with rates of 7.7%, 4.2% and 4.7% for chlorthalidone, amlodipine and lisinopril, respectively (p < 0.05 for both amlodipine and lisinopril vs. chlorthalidone) (58). Despite these differences, the risk of combined cardiovascular disease events was similar in those with the metabolic syndrome as in those without, and in those who developed diabetes and in those who did not (58). In a separate subgroup analysis that compared cardiovascular disease outcomes by race in non-diabetic patients with and without the metabolic syndrome, long-term cardiovascular outcomes were similar across the treatment groups, with the lack of cardiovascular benefit especially striking in black patients with the metabolic syndrome (59).

These analyses have not resolved the controversy regarding the relationship between new-onset diabetes and cardiovascular disease risk and have led some investigators to question whether diuretic- or β-blocker-associated diabetes confers the same clinical implications as new-onset diabetes that develops outside the setting of antihypertensive therapy (60).

Further clarification of the comparative value of antihypertensive combinations comparing the use of a glucose neutral agent such as a CCB with a thiazide-type diuretic will come from the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension trial. In this trial, the high-risk hypertensive patients were initially randomised to a fixed-dose combination of either an ACE inhibitor/thiazide-type diuretic or an ACE inhibitor/CCB. New onset diabetes is a prespecified secondary end-point (61).

The question of whether preventing new-onset diabetes is associated with a reduction in cardiovascular disease events may be resolved with the results of two ongoing large-scale clinical trials – Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) (62) and ACE Inhibitor-based vs. Diuretic-based Antihypertensive Primary Treatment in Patients with PreDiabetes (ADaPT) (63). NAVIGATOR is a multinational, double-blind, placebo-controlled, 2 × 2 factorial study to determine the effects of the meglitinide antidiabetic drug nateglinide and of valsartan on two primary outcomes: prevention of new-onset diabetes and prevention of cardiovascular disease events (death, myocardial infarction, stroke and hospitalisation for heart failure). A total of 9306 participants aged 50 years or older with impaired fasting glucose and known cardiovascular disease or aged 55 years or older with impaired glucose tolerance and 1 or more cardiovascular disease risk factors were randomised in a 1 : 1 : 1 : 1 ratio to one of four possible treatment combinations: nateglinide with valsartan, nateglinide with valsartan-placebo, nateglinide-placebo with valsartan or nateglinide-placebo with valsartan-placebo. The results of this events-driven trial are expected to be reported in 2009 (62). ADaPT, which includes 2015 patients with hypertension, impaired fasting glucose, and A1C 6–6.5%, is an open-label trial designed to compare the effect on new-onset diabetes of antihypertensive treatment based on ramipril vs. treatment based on diuretics or β-blockers. The results of the 4-year study are expected in 2010 (63).

In the interim, the effects of antihypertensive therapy and the presence of comorbid risk factors on the risk of new-onset diabetes and cardiovascular disease should be carefully evaluated for each patient. Indeed, in post hoc analyses of ASCOT-BPLA (40) and VALUE (64), baseline fasting plasma glucose level and body mass index – two measurable, modifiable risk factors – were the strongest predictors of new-onset diabetes. In ASCOT-BPLA, randomisation of the amlodipine ± perindopril treatment arm was the strongest protective factor (40), highlighting the importance of including a RAS inhibitor as part of the antihypertensive regimen in patients at high risk for diabetes and cardiovascular disease.

Possible mechanisms
The mechanisms by which RAS inhibition reduces the development of diabetes remain to be established. ACE inhibitors and ARBs improve insulin sensitivity, possibly caused by their vasodilatory effects, which result in increased blood flow and increased insulin delivery to peripheral skeletal muscles (65–67). ACE
inhibitors and ARBs may also improve glucose metabolism by enhancing insulin receptor signalling in skeletal muscle and fat cells (68). RAS blockade is associated with a reduction in renal potassium loss, which may lead to enhanced β-cell secretion of insulin (66,68) and may protect pancreatic islets from glucotoxicity and oxidative stress (67). In addition, ARBs increase levels of adiponectin, an adipose-derived protein thought to enhance insulin sensitivity (67,69). Finally, some ARBs activate peroxisome proliferator-activated receptor-γ, a well-established target for insulin-sensitising antidiabetic drugs (66,69).

Conclusions

Diabetes is a worldwide epidemic with the substantial health ramifications. Because cardiovascular disease is the leading cause of death in patients with diabetes, the prevention of diabetes has the potential to reduce the burden of cardiovascular disease. Evidence suggests that lifestyle modifications aimed at weight reduction and increased physical activity and antidiabetic pharmacologic interventions reduce the risk of new-onset diabetes. Although there is ample evidence that antihypertensive therapy with RAS inhibitors is associated with a reduced risk of new-onset diabetes compared with other classes of antihypertensive drugs, the prognostic significance of this differential effect remains controversial. No study using antihypertensive therapy has yet demonstrated a commensurate reduction in cardiovascular disease risk, and secondary analyses of trials of RAS blockers have provided conflicting results. It appears reasonable to avoid traditional β-blocker and thiazide-type diuretic therapy in the minority of patients who have impaired fasting glucose or impaired glucose tolerance and whose blood pressure can be controlled on single-agent antihypertensive therapy. In these patients, the use of ACE inhibitor and ARB therapy, like in those with the metabolic syndrome, may have an advantage in decreasing the subsequent risk for new-onset diabetes. When blood pressure is not effectively controlled with ACE inhibitor or ARB therapy, the addition of a thiazide-type diuretic is clearly indicated as the benefits of achieving blood pressure control appear to outweigh any negative effects on glucose metabolism. Whether a CCB should be added before a thiazide-type diuretic remains uncertain. The results of the large-scale NAVIGATOR study may help resolve the issue of whether treatment of high-risk patients with an antidiabetic drug or an ARB reduces the incidence of new-onset diabetes and cardiovascular disease.

For now, lifestyle measures including weight loss and exercise as well as the importance of addressing global cardiovascular disease risk through the use of statin and aspirin therapy may be a more effective strategy to improve vascular health and limit insulin resistance in patients with hypertension. Additionally, achieving blood pressure control with agents that do not worsen insulin resistance should be attempted; failing that, vasodilating β-blockers and low-dose diuretics must be used to reduce risk. Physicians should be aware that in most cases multiple antihypertensive agents will be needed. While keeping serum potassium levels normal, diuretics should be considered when blood pressure goals have not been achieved in patients with impaired fasting glucose. When used in this setting, although new-onset diabetes may be more likely to occur, cardiovascular outcomes are still improved by achieving additional blood pressure reduction.

Acknowledgement

The author wishes to thank Tanja Schub of Landmark Programs for editorial support.

References

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047–53.
2. Cowie CC, Rust KF, Byrd-Holt DD et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population. Diabetes Care 2006; 29: 1263–8.
3. Buse JB, Ginsberg HN, Bakris GL et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007; 115: 114–26.
4. Grundy SM, Cleeman JJ, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735–52.
5. Alderman MH, Cohen H, Madhavan S. Diabetes and cardiovascular events in hypertensive patients. Hypertension 1999; 33: 1130–4.
6. National Institute of Diabetes and Digestive and Kidney Diseases. National Diabetes Statistics Fact Sheet: General Information and National Estimates on Diabetes in the United States, Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, 2005.
7. Mokdad AH, Ford ES, Bowman ES et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289: 76–9.
8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation 2002; 106: 3143–420.
9. Nakashishi N, Takatorige T, Fukuda H et al. Components of the metabolic syndrome as predictors of cardiovascular disease and type 2 diabetes in middle-aged Japanese men. Diabetes Res Clin Pract 2004; 64: 59–70.
10. Almdal T, Scharling H, Jensen JS, Vestergaard H. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13 000 men and women with 20 years of follow-up. Arch Intern Med 2004; 164: 1422–6.
11 The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–86.
12 UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 857–65.
13 Selvin E, Marfinovalou S, Berenberg G et al. Meta-analysis: glycated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141: 421–31.
14 Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643–53.
15 The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560–72.
16 The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545–59.
17 Cefalu WT. Glycemic targets and cardiovascular disease. N Engl J Med 2009; 361: 753–9.
18 American College of Endocrinology Task Force on Pre-Diabetes. American College of Endocrinology Consensus Statement on the diagnosis and management of pre-diabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? http://www.diabetes.org/diabetes-statistics/prevalence.jsp (accessed August 2008).
19 Nathan DM, Davidson MB, DeFronzo RA et al. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007; 30: 753–9.
20 American College of Endocrinology Task Force on Pre-Diabetes. American College of Endocrinology Consensus Statement on the diagnosis and management of pre-diabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? http://www.diabetes.org/diabetes-statistics/prevalence.jsp (accessed August 2008).
21 American Diabetes Association. Total prevalence of diabetes & pre-diabetes. http://www.diabetes.org/diabetes-statistics/prevalence.jsp (accessed August 2008).
22 American Diabetes Association. Total prevalence of diabetes & pre-diabetes. http://www.diabetes.org/diabetes-statistics/prevalence.jsp (accessed August 2008).
23 Tuomilehto J, Lindstrom J, Eriksson JG et al., for the Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343–50.
24 Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403.
25 Orchard TJ, Temporossi M, Goldberg R et al., Diabetes Prevention Program Research Group. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 2005; 142: 611–9.
26 Buchanan TA, Xiang AH, Peters RK et al. Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002; 51: 2796–803.
27 Chiasson J-L, Josse RG, Gomis R et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072–7.
28 Chiasson J-L, Josse RG, Gomis R et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM Trial. JAMA 2003; 290: 486–94.
29 DREAM (Diabetes REDUction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368: 1096–105.
30 The ORIGIN Trial Investigators. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J 2008; 155: 26–32.e6.
31 Torgerson JS, Hauptsan J, Boldrin MN, Sjostrom L. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) study. Diabetes Care 2004; 27: 155–61.
32 Freeman DJ, Norrie J, Sattar N et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103: 357–62.
33 Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005–16.
34 Keen A, Colquhoun D, Best J et al., LIPID Study Group. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 2003; 26: 2713–21.
35 Sever PS, Dahlöf B, Poulter NR et al., ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149–58.
36 Gress TW, Nieto FJ, Shahar E, Wolford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus: atherosclerosis risk in communities study. N Engl J Med 2000; 342: 905–12.
37 Bays HE, Batza DD, Clark NG et al. Prevalence of self-reported diagnosis of diabetes mellitus and associated risk factors in a national survey in the US population: SHIELD (Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes). BMC Public Health 2007; 7: 277.
38 Chobanian AV, Bakris GL, Black HR et al., and the National High Blood Pressure Education Program Coordinating Committee Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206–52.
39 Dahlöf B, Sever PS, Poulter NR et al., for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendrofluazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised trial. Lancet 2005; 366: 895–906.
40 Gupta AK, Dahlöf B, Dobson J et al. Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm and the relative influence of antihypertensive medication. Diabetes Care 2008; 31: 982–8.
41 Hansson L, Lindholm LH, Niskanen L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomised trial. Lancet 1999; 353: 611–6.
42 Yusuf S, Sleight P, Fague J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145–53.
43 ALLHAT Officers and Coordinators of the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting-enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–9.
45 Dahlöf B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. The LIFE study group. Lancet 2002; 359: 995–1003.
46 Lithell H, Hansson L, Skoog I et al. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875–86.
47 Pleffer MA, Swedberg K, Granger CB et al., for the CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759–66.
48 Julius S, Kjeldsen SE, Weber M et al., for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–31.
49 Andraws R, Brown DL. Effect of inhibition of the renin–angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials). Am J Cardiol 2007; 99: 1006–12.
50 Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369: 201–7.
51 DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006; 355: 1531–62.
52 DREAM Trial Investigators. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care 2008; 31: 1007–14.
53 Macfarlane DF, Paterson KE, Fisher M. Cardiovascular drugs as antidiabetic agents: evidence for the prevention of type 2 diabetes. Diabetes Obes Metab 2008; 10: 533–44.
54 Aksnes TA, Kjeldsen SE, Rostrup M, Omvik P, Hua TA, Julius S. Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial population. Hypertension 2007; 50: 467–73.
55 Verdecchia P, Angeli F, Reboldi G. New-onset diabetes, antihypertensive treatment, and outcome. Hypertension 2007; 50: 459–60.
56 ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–59.
57 The Telmisartan Randomised Assessment in ACE InTolera nt subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angioten sin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008; 372: 1174–83.
58 Black HR, Davis B, Barzilay J et al. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlopine, or losinpril as initial treatment for hypertension. Diabetes Care 2008; 31: 353–60.
59 Wright JT Jr, Harris-Haywood S, Pressel S et al. Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2008; 168: 267–77.
60 Bloch M, Basile J. Development of new-onset diabetes mellitus is associated with an increased risk for cardiac morbidity: the VALUE trial. J Clin Hypertens 2007; 9: 905–7.
61 Jamerson KA, for the Avoiding Cardiovascular Events through Combination therapy in Patients Living with Systolic Hypertension Trial. The first hypertension trial comparing the effects of two fixed-dose combination therapy regimens on cardiovascular events: Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH). J Clin Hypertens (Greenwich) 2008; 4 (Suppl 3): 29–35.
62 Califf RM, Boothell M, Haffter SM et al., for the NAVIGATOR Study Group. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial. Am Heart J 2008; 156: 623–32.
63 Zidek W, Schrader J, Luder S et al. First-line antihypertensive treatment in patients with pre-diabetes: rationale, design and baseline results of the ADAPT investigation. Cardiovasc Diabetol 2008; 7: 22.
64 Aksnes TA, Kjeldsen SE, Rostrup M, Storset Ø, Hua TA, Julius S. Predictors of new-onset diabetes mellitus in hypertensive patients: the VALUE trial. J Hum Hypertens 2008; 22: 520–7.
65 Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 2005; 23: 463–73.
66 Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 2006; 24: 3–10.
67 Ostergren J. Renin-angiotensin-system blockade in the prevention of diabetes. Diabetes Res Clin Pract 2007; 76S: S13–21.
68 McGuire DK, Winterfield JR, Rylewski JA, Ferrannini E. Blocking the renin-angiotensin–aldosterone system to prevent diabetes mellitus. Diabetes Vasc Dis Res 2008; 5: 59–66.
69 Perkins JM, Davis SN. The renin-angiotensin–aldosterone system: a pivotal role in insulin sensitivity and glycemic control. Curr Opin Endocrinol Diabetes Obes 2008; 15: 147–52.